Recursion Pharmaceuticals Inc Asset Resilience Ratio
Recursion Pharmaceuticals Inc asset resilience ratio. Recursion Pharmaceuticals Inc (RXRX) has an Asset Resilience Ratio of 0.00% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Recursion Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Recursion Pharmaceuticals Inc (2020–2022)
Asset resilience ratio of Recursion Pharmaceuticals Inc from 2020 to 2022. This chart shows how Recursion Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read RXRX total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Recursion Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Recursion Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Recursion Pharmaceuticals Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Recursion Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Recursion Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Recursion Pharmaceuticals Inc Asset Resilience Ratio by Year (2020–2022)
Recursion Pharmaceuticals Inc asset resilience ratio by year from 2020 to 2022. The table below shows the annual Asset Resilience Ratio data for Recursion Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | $0.00 | $701.29 Million | -- |
| 2021-12-31 | 37.92% | $231.45 Million | $610.35 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $298.58 Million | -- |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenom… Read more